Neurotransmitter and Neurotrophic Factor-Secreting Cell Line Grafting for the Treatment of Parkinson’s Disease

  • Isao Date
  • Tetsuro Shingo
  • Takao Yasuhara
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Amyotrophic Lateral Sclerosis PC12 Cell Neurotrophic Factor Chromaffin Cell Cell Grafting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral transplants. Brain Res 1979;177:555–560.PubMedCrossRefGoogle Scholar
  2. 2.
    Date I. Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies. Brain Res Bull 1996;40:1–19.PubMedCrossRefGoogle Scholar
  3. 3.
    Date I, Ohmoto T, Imaoka T, et al. Cografting with polymer-encapsulated human nerve growth factor-secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats. J Neurosurg 1996;84:1006–1012.PubMedGoogle Scholar
  4. 4.
    Date I, Imaoka T, Miyoshi Y, et al. Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve: case report. J Neurosurg 1996;84:685–689.PubMedGoogle Scholar
  5. 5.
    Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696–699.PubMedCrossRefGoogle Scholar
  6. 6.
    Emerich DF, Winn SR, Christenson L, et al. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 1992;16:437–447.PubMedCrossRefGoogle Scholar
  7. 7.
    Yoshida H, Date I, Shingo T, et al. Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: a preclinical primate study. J Neurosurg 2003;98:874–881.PubMedGoogle Scholar
  8. 8.
    Date I, Shingo T, Yoshida H, et al. tGrafting of encapsulated dopamine-secreting cells in Parkinson's disease: long-term primate study. Cell Transplant 2000;9:705–709.PubMedGoogle Scholar
  9. 9.
    Subramanian T, Emerich DF, Bakay RA, et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant 1997;6:469–477.PubMedCrossRefGoogle Scholar
  10. 10.
    Date I, Shingo T, Ohmoto T, et al. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Exp Neurol 1997;147:10–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Date I, Shingo T, Yoshida H, et al. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 2001;10:397–401.PubMedGoogle Scholar
  12. 12.
    Fujiwara K, Date I, Shingo T, et al. Reduction of infarct volume and apoptosis by grafting of encapsulated basic fibroblast growth factor-secreting cells in a model of middle cerebral artery occlusion in rats. J Neurosurg 2003;99:1053–1062.PubMedCrossRefGoogle Scholar
  13. 13.
    Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004;19:1494–1504.PubMedCrossRefGoogle Scholar
  14. 14.
    Shingo T, Date I, Yoshida H, et al. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res 2002;69:946–954.PubMedCrossRefGoogle Scholar
  15. 15.
    Uchida S, Suzuki Y, Araie M, et al. Factors secreted by human amniotic epithelial cells promote the survival of rat retinal ganglion cells. Neurosci Lett 2003;341:1–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Buchser E, Goddard M, Heyd B, et al. Immunoisolated xenogenic chromaffin cell therapy for chronic pain: initial clinical experience. Anesthesiology 1996;85:1005–1012.PubMedCrossRefGoogle Scholar
  17. 17.
    Bachoud-Levi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000;11:1723–1729.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Isao Date
    • 1
  • Tetsuro Shingo
  • Takao Yasuhara
  1. 1.Department of Neurological SurgeryOkayama UniversityOkayama 700-8558Japan

Personalised recommendations